Jci_page_head_homepage_01 Jci_page_head_homepage_02
Wendy K. Roberts, Ilana J. Deluca, Ashby Thomas, John Fak, Travis Williams, Noreen Buckley, Athanasios G. Dousmanis, Jerome B. Posner, Robert B. Darnell
Published in Volume 119, Issue 7
J Clin Invest. 2009; 119(7):2042–2051 doi:10.1172/JCI36131
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Jci36131
Figure 5
Hu patient T cells are skewed toward production of IL-13 and IL-4 but not IFN-γ.

(A) ELISPOT assay demonstrating the number of IL-13–producing, Hu-specific CD8+ cells in a bulk, unsorted Hu157 culture from patient 2 (same cells as in Figure 3A). (B) ELISPOT results using sorted cells from patient 3, comparing IFN-γ and IL-13 responses. Error bars in A and B indicate SD of the mean of triplicate wells. (C) Intracellular staining for IFN-γ, IL-13, and IL-4, using sorted T cells from Hu patient 2. The top 2 rows show Hu157 cells after irrelevant (HIV) and Hu157 peptide stimulation. The bottom row shows staining of M1-specific cells after irrelevant and M1 peptide stimulation. (D) Staining for Hu157- and M1-specific CD8+ T cells with lytic activity, using CD107a antibody combined with intracellular cytokine staining. The percentages of cells in each quadrant are denoted in the corners of the plots in C and D. (E) Intracellular staining of in vitro–skewed T cells showing production of IL-13 by CD8+ T cells and CD4+ T cells (positive controls) cultured in the presence of Th2 conditions (IL-4) but not Th1 conditions (IL-12, anti–IL-4). Numbers in corners represent the percentage of IL-13+ cells.